Double Bond Pharmaceutical receives patent in the United States for the BeloGal® platform
Double Bond Pharmaceuticals patent application for organ-specific administration of hydrophilic cancer drug to the liver which forms the basis for the BeloGal® technology platform has been granted in the United States. Patent approval provides protection for the technology platform BeloGal® and products on the US market at least through 2035. "It is the company's first licensed patent and we are very pleased that it concerns the largest market in the world - the United States. With the patent, we have achieved an important interim goal for the commercialization of our front-line product